Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
DEXTROSE 5% AND SODIUM CHLORIDE 0.225% IN PLASTIC CONTAINER vs AMIKIN IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Dextrose is a monosaccharide that serves as a source of calories and energy, replenishing blood glucose levels. Sodium chloride provides electrolytes for fluid and electrolyte balance.
Aminoglycoside antibiotic that binds to the 30S ribosomal subunit, causing misreading of m RNA and inhibition of protein synthesis.
FDA: For intravenous administration as a source of water, calories, and electrolytes in patients requiring parenteral fluid therapy.,Off-label: Treatment of hypovolemia, hyponatremia, and hyperkalemia.
Treatment of serious gram-negative bacterial infections,Septicemia,Lower respiratory tract infections,Intra-abdominal infections,Complicated urinary tract infections,Skin and soft tissue infections,Bone and joint infections,Burn infections,Perioperative prophylaxis in high-risk patients
Intravenous infusion; dosing depends on patient's fluid and electrolyte needs. Typical adult dose: 0.9% sodium chloride equivalent at 100-200 m L/hour, but adjust based on serum sodium, glucose, and volume status.
15 mg/kg/day IV divided every 8-12 hours (usual adult dose: 15 mg/kg/day).
Dextrose: Not applicable as it is rapidly metabolized. Sodium: Not applicable (homeostatically regulated). Chloride: Not applicable (follows sodium). Clinical context: Half-life concepts do not apply; steady state for electrolytes depends on infusion rate and renal function.
Terminal elimination half-life: 2–3 hours in patients with normal renal function; may be prolonged to 30–60 hours in anuria.
Dextrose is metabolized via glycolysis and the tricarboxylic acid cycle. Sodium chloride is not metabolized.
Primarily excreted unchanged by glomerular filtration. Minimal hepatic metabolism.
Renal: Dextrose is metabolized to carbon dioxide and water, with negligible renal excretion of unchanged dextrose. Sodium and chloride are primarily excreted renally with >90% of filtered load reabsorbed; excess is excreted in urine. Biliary/fecal: Negligible.
Renal excretion of unchanged drug via glomerular filtration; >90% eliminated unchanged in urine within 24 hours. Biliary/fecal excretion <1%.
Dextrose: Not bound. Sodium: Not bound. Chloride: Not bound.
Low protein binding; 0–11% bound, primarily to albumin.
Dextrose: 0.2–0.3 L/kg (total body water). Sodium and chloride: 0.2–0.3 L/kg (extracellular fluid). Clinical meaning: Distributes predominantly in extracellular fluid; expands plasma and interstitial volume.
Vd: 0.25–0.4 L/kg; approximates extracellular fluid volume. Increased in edema, ascites; decreased in dehydration.
IV: 100% (by definition).
Intravenous: 100% bioavailable. Not administered orally (negligible absorption).
For GFR 30-60 m L/min: no specific adjustment; monitor volume status and serum electrolytes. For GFR <30 m L/min: use with caution; may require volume restriction and monitoring for hyperchloremic metabolic acidosis.
For GFR 30-59 m L/min: extend interval to every 12-24 hours; GFR 15-29 m L/min: every 24-48 hours; GFR <15 m L/min (not on dialysis): every 48-96 hours or consider dosing based on serum levels.
No specific Child-Pugh based adjustments; use with caution in patients with cirrhosis due to risk of fluid overload and hyponatremia.
No specific Child-Pugh based modifications; monitor renal function and drug levels.
Weight-based infusion: 0.9% sodium chloride equivalent at 4-8 m L/kg/hour; adjust based on serum sodium and glucose levels. For maintenance: 100 m L/kg/day for first 10 kg, 50 m L/kg/day for next 10 kg, 20 m L/kg/day for additional weight.
Neonates: 15-20 mg/kg/day IV divided every 12 hours; Infants and Children: 15-22.5 mg/kg/day IV divided every 8-12 hours.
Use with caution; lower initial infusion rates (e.g., 50-100 m L/hour) due to increased risk of fluid overload and electrolyte disturbances. Monitor serum sodium and glucose frequently.
Adjust dose based on renal function; monitor serum creatinine and trough levels; usual starting dose: 15 mg/kg/day with extended intervals per renal function.
None.
Aminoglycosides can cause nephrotoxicity and ototoxicity. Neurotoxicity (including vestibular and auditory) may occur even at normal doses. Risk is greater in patients with renal impairment, pre-existing hearing loss, or prolonged use. Monitor renal function and eighth cranial nerve function.
Risk of hyperglycemia and hyperosmolar syndrome in patients with diabetes mellitus or impaired glucose tolerance.,Risk of fluid overload, especially in patients with renal impairment or cardiac disease.,Risk of dilutional hyponatremia, particularly in patients with increased ADH production.
Monitor renal function and audiometric tests,Adjust dose based on renal function,Risk of neuromuscular blockade, especially in patients with neuromuscular disorders,Avoid concurrent use of other nephrotoxic or ototoxic drugs,Use caution in neonates, elderly, and patients with dehydration
Hypersensitivity to any component.,Clinically significant hyperglycemia or hypernatremia.,Use in patients with intracranial or intraspinal hemorrhage, or conditions causing severe dehydration with anuria.
Hypersensitivity to amikacin or other aminoglycosides,Myasthenia gravis (relative due to risk of neuromuscular blockade)
No direct food interactions. However, sodium content (0.225% = 34.5 m Eq/L) should be considered in patients on sodium-restricted diets. Dextrose may affect glucose tolerance; monitor intake in diabetic patients.
No clinically significant food interactions. Maintain adequate hydration. Avoid excessive alcohol consumption.
Dextrose and sodium chloride are physiologic components that are not known to be teratogenic; no increased risk of congenital anomalies has been reported.
Aminoglycosides like amikacin cross the placenta. First trimester: No evidence of major malformations, but risk cannot be excluded. Second and third trimesters: Potential for fetal ototoxicity (eighth cranial nerve damage) and nephrotoxicity, especially with high doses or prolonged use. Avoid unless compelling indication.
Excreted in breast milk; M/P ratio not established. Dextrose and sodium chloride are normal constituents of milk; use during lactation is considered safe.
Minimal excretion into breast milk (M/P ratio unknown but expected low). No reports of adverse effects in nursing infants from maternal amikacin use. Caution with infant renal impairment or premature infants due to potential accumulation. Use only if necessary.
No dose adjustment required; pharmacokinetics of dextrose and sodium chloride are not significantly altered in pregnancy. Use caution in patients with gestational diabetes or preeclampsia.
Increased renal clearance in pregnancy may lower serum levels; consider higher doses based on therapeutic drug monitoring. Adjust for renal impairment if present. Standard initial dosing: 15 mg/kg/day IV/IM divided q8-12h, with level-guided adjustments.
This hypotonic solution (225 m Osm/L) is suitable for maintenance hydration in normonatremic patients. Monitor serum sodium to avoid hyponatremia, especially in children, elderly, or those with impaired renal function. Do not use for resuscitation or in patients with hyponatremia. Contains 5% dextrose providing 170 kcal/L; consider in catabolic states.
Amikacin is an aminoglycoside antibiotic with concentration-dependent bactericidal activity. Monitor peak (20-30 mcg/m L) and trough (<10 mcg/m L) serum levels to optimize efficacy and minimize toxicity. Adjust dose based on renal function (Cr Cl). Ototoxicity (vestibular and cochlear) and nephrotoxicity are dose-limiting; audiometry and renal function tests are mandatory. Extended-interval dosing (15-20 mg/kg once daily) is preferred for most indications. Avoid concurrent use with other nephrotoxic drugs (e.g., vancomycin, loop diuretics).
This solution provides water, sugar, and salt to maintain hydration and energy.,Tell your doctor if you have swelling (edema), heart failure, or kidney problems.,Inform your doctor if you are on a low-sodium diet.,You may experience weight gain or swelling if too much fluid is given.,Do not self-adjust the infusion rate.
Take exactly as prescribed; do not skip doses or stop early.,Drink plenty of fluids to stay hydrated.,Report hearing changes (ringing in ears, dizziness) immediately.,Report decreased urine output or swelling in legs.,Avoid taking other medications without consulting your doctor, especially pain relievers like ibuprofen.,This medication is given intravenously; you may feel warmth or tingling during infusion.
"Lithium cation may increase the excretion rate of Sodium chloride which could result in a lower serum level and potentially a reduction in efficacy."
"The risk or severity of adverse effects can be increased when Sodium chloride is combined with Tolvaptan."
"Lithium cation may increase the excretion rate of Sodium chloride which could result in a lower serum level and potentially a reduction in efficacy."
"The risk or severity of adverse effects can be increased when Sodium chloride is combined with Tolvaptan."
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about DEXTROSE 5% AND SODIUM CHLORIDE 0.225% IN PLASTIC CONTAINER vs AMIKIN IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, answered by our medical review team.
DEXTROSE 5% AND SODIUM CHLORIDE 0.225% IN PLASTIC CONTAINER is a Electrolyte that works by Dextrose is a monosaccharide that serves as a source of calories and energy, replenishing blood glucose levels. Sodium chloride provides electrolytes for fluid and electrolyte balance.. AMIKIN IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER is a Electrolyte that works by Aminoglycoside antibiotic that binds to the 30S ribosomal subunit, causing misreading of m RNA and inhibition of protein synthesis.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between DEXTROSE 5% AND SODIUM CHLORIDE 0.225% IN PLASTIC CONTAINER and AMIKIN IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER depend on the specific clinical indication. These are both Electrolyte agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of DEXTROSE 5% AND SODIUM CHLORIDE 0.225% IN PLASTIC CONTAINER is: Intravenous infusion; dosing depends on patient's fluid and electrolyte needs. Typical adult dose: 0.9% sodium chloride equivalent at 100-200 m L/hour, but adjust based on serum sodium, glucose, and volume status.. The standard adult dose of AMIKIN IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER is: 15 mg/kg/day IV divided every 8-12 hours (usual adult dose: 15 mg/kg/day).. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
A moderate-severity drug interaction has been identified when combining DEXTROSE 5% AND SODIUM CHLORIDE 0.225% IN PLASTIC CONTAINER and AMIKIN IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER. The risk or severity of adverse effects can be increased when Sodium chloride is combined with Tolvaptan. Consult your prescriber before combining these medications.
The maternal-fetal safety profiles differ. DEXTROSE 5% AND SODIUM CHLORIDE 0.225% IN PLASTIC CONTAINER is classified as Category A/B. Dextrose and sodium chloride are physiologic components that are not known to be teratogenic; no increased risk of congenital anomalies has been reported.. AMIKIN IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER is classified as Category A/B. Aminoglycosides like amikacin cross the placenta. First trimester: No evidence of major malformations, but risk cannot be excluded. Second and third trimesters: Potential for fetal. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.